Drugs / MSD-001
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT06702332 Comparator | Nov 2024 → Jun 2025 | mental disorder | Mindstate Design Labs | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-09-24 | Mindstate Design Labs | Topline study MSD-001 clinical trial results and lead fixed dose combination program announcement mindstate.design ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MSD-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06702332 ↗ |
| Route | Oral | “Orally Administered MSD-001” NCT06702332 ↗ |